AdaptHealth (AHCO) Director Discloses Sale of 8,200 Shares at $9.73
Rhea-AI Filing Summary
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
Positive
- Transparent disclosure of the share sale with weighted average price and price range provided
- Continued ownership of 50,045 shares is reported after the transactions
- Procedural compliance shown via attorney-in-fact signature and incorporated power of attorney
Negative
- Reduction in holdings by 8,200 shares reported on 08/22/2025
- Sale realized at a modest price (weighted average $9.73 per share)
Insights
TL;DR: Director sold a modest block of shares; filing documents the sale price range and remaining holdings.
The Form 4 discloses an outright sale of 8,200 common shares at a weighted average price of $9.73, with individual transaction prices between $9.60 and $9.85. The report confirms continued direct ownership of 50,045 shares post-sale. From an analytical standpoint, the filing provides clear transaction detail and preserves transparency about insider holdings and pricing; it does not include additional financial metrics or context about timing beyond the 08/22/2025 transaction date.
TL;DR: Disclosure appears compliant and properly executed via power of attorney; sale details are fully footnoted.
The Form 4 is filed for one reporting person and includes an explicit footnote explaining the weighted average price and price range, plus a reference to a previously filed power of attorney. The document includes the attorney-in-fact signature block dated 08/22/2025. These elements indicate procedural compliance with Section 16 reporting requirements; the filing contains no information about any planned trading programs or contractual plans.